top of page

ASCO 2026: Olema Oncology's CEO Sean Bohen highlights new KAT6 data in breast and prostate cancer, and updates us on the progress of palazestrant's pivotal trials

  • 7 minutes ago
  • 1 min read

He discusses the potential utility of KAT6 after presenting monotherapy data, and how it could be used in combination with palazestrant (a complete estrogen receptor antagonist). Plus, learning from the field in the estrogen receptor space, and an update on the progress of Olema's own pivotal tirals. The company's OPERA-1 monotherapy phase 3 of palazestrant is schedule to read in the fall.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page